Truist Financial sets a new price target of $16 for CorMedix Therapeutics (NASDAQ:CRMD), indicating an 84.95$127 million for Q4 and $400 million for the full year of 2025.The company's adjusted EBITDA for Q4 is expected to be between$77 million and $81 million, showcasing strong operational performance.CorMedix Therapeutics, trading on the NASDAQ under the symbol CRMD, is a biopharmaceutical company focused on developing and commercia ...